Clinical Trial Update: A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of MGCD265 in combination with erlotinib or docetaxel in patients with advanced malignancies, including non-small cell lung cancer, has been ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ERLOTINIB (Erlotinib)
• MGCD265 (MGCD265)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Advanced Malignancies, Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED